在癌症中准MHC-I内体-解体贩运途径:从机制到免疫疗法
Di Ye1, Shuang Zhou1, Xinyu Dai1
1Division of Abdominal Cancer, Department of Medical Oncology, Cancer Center and Laboratory of Molecular Targeted Therapy in Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan Province 610041, China.
瘤细胞通过减少表面主要基因相容性复合物I类 (MHC-I) 表达来逃避免疫检查点阻塞 (ICB) 治疗. 了解MHC-I lysosomal降解为提高癌症免疫疗法的有效性提供了新的策略.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 免疫检查点阻塞 (ICB) 疗法看起来很有前途,但由于天生的耐药性,它面临着低于最佳的反应率.
- 低CD8+细胞毒性T细胞 (CTL) 透率,与抗原呈现不足有关,是ICB耐药性的关键因素.
- 主体组织相容性复合体I类 (MHC-I) 在瘤细胞上的表达对于CTL识别和瘤清除至关重要.
研究的目的:
- 审查膜MHC-I转移到细胞质和溶酶体降解的机制.
- 要突出瘤细胞如何通过调节MHC-I表达来逃避CTL检测和清除.
- 总结针对这些途径的新型治疗策略,以改善癌症免疫疗法.
主要方法:
- 关于内体-溶体MHC-I传输的近期进展的文献综述.
- 对减少表面MHC-I表达的瘤细胞机制的分析.
- 对针对MHC-I途径的治疗干预措施的当前知识的综合.
主要成果:
- 瘤细胞采用各种机制来减少表面MHC-I,损害抗原呈现和免疫逃避.
- 内体-溶解体通路在调节MHC-I表面表达和稳定性方面发挥着重要作用.
- 针对MHC-I的贩运和退化是一个潜在的战略,以克服ICB的抗性.
结论:
- 了解MHC-I调控对于提高ICB疗效至关重要.
- 针对MHC-I lysosomal降解的治疗策略可能会增强抗瘤免疫力.
- 本综述提供了通过调节MHC-I通路来优化癌症免疫治疗的见解.
更多相关视频
09:53Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
Published on: February 6, 2017
09:01Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Antigen Processing Pathways
MHC Class I: Presenting Endogenous...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
